Trial · NCT03897036

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

NCT03897036, Phase 1, Completed, Senhwa Biosciences, Inc.; results first posted 2025-05-20

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC). Trials, record NCT03897036. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03897036

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
NCT number: NCT03897036
Status: Completed
Phases: Phase 1
Enrollment: 25 participants, actual
Lead sponsor: Senhwa Biosciences, Inc.
Conditions: Carcinoma, Basal Cell
Interventions: CX-4945
First posted: 2019-04-01
Last updated: 2025-05-20
Results first posted: 2025-05-20

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Determination of RP2D	Cycle 1, twenty-eight (28) day continuous dosing schedule	Determination of RP2D for the expansion cohorts

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Determination of RP2D	Cycle 1, twenty-eight (28) day continuous dosing schedule		mg	NUMBER

Source ClinicalTrials.gov

Results by group1

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Determination of RP2D	Treatment-Duration-Increment		1000		mg

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Treatment-Duration-Increment	8
Overall Study	STARTED	Expansion	17
Overall Study	COMPLETED	Treatment-Duration-Increment	8
Overall Study	COMPLETED	Expansion	16
Overall Study	NOT COMPLETED	Treatment-Duration-Increment	0
Overall Study	NOT COMPLETED	Expansion	1

Source ClinicalTrials.gov

Adverse events168

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Diarrhoea	Gastrointestinal disorders	Treatment-Duration-Increment	8	8
other	Diarrhoea	Gastrointestinal disorders	Expansion	14	17
other	Nausea	Gastrointestinal disorders	Treatment-Duration-Increment	5	8
other	Nausea	Gastrointestinal disorders	Expansion	9	17
other	Vomiting	Gastrointestinal disorders	Treatment-Duration-Increment	3	8
other	Vomiting	Gastrointestinal disorders	Expansion	4	17
other	Constipation	Gastrointestinal disorders	Treatment-Duration-Increment	0	8
other	Constipation	Gastrointestinal disorders	Expansion	4	17
other	Abdominal Pain	Gastrointestinal disorders	Treatment-Duration-Increment	2	8
other	Abdominal Pain	Gastrointestinal disorders	Expansion	1	17

1 to 10 of 168Source ClinicalTrials.gov

See all 168 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Treatment-Duration-Increment	0	8
Total, all-cause mortality	Expansion	1	17
Total, other adverse events	Treatment-Duration-Increment	8	8
Total, other adverse events	Expansion	16	17
Total, serious adverse events	Treatment-Duration-Increment	2	8
Total, serious adverse events	Expansion	3	17

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Treatment-Duration-Increment vs Expansion: deaths from any cause	Trial comparisons
Treatment-Duration-Increment vs Expansion: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03897036

GET https://conductscience.org/api/trials/v1/NCT03897036/events?page=2

API reference For AI assistants